Trifluridine da tipiracil tare da bevacizumab sun amince da FDA don maganin ciwon daji na metastatic a baya.

trifluridine da tipiracil
Cibiyar Abinci da Drug ta amince da trifluridine da tipiracil (LONSURF, Taiho Oncology, Inc.) tare da bevacizumab, don ciwon daji na launin fata (mCRC) wanda aka bi da shi a baya tare da fluoropyrimidine-, oxaliplatin- da irinotecan-tushen chemotherapy, wani anti-VEGF nazarin halittu far, da kuma idan RAS-nau'in daji, maganin anti-EGFR. FDA ta riga ta amince da LONSURF mai wakili ɗaya don wannan nuni a cikin Satumba 2015.

Share Wannan Wallafa

Agusta 2023: Don ciwon daji na launin fata (mCRC) wanda aka riga aka bi da shi tare da fluoropyrimidine, oxaliplatin, da irinotecan na tushen chemotherapy, maganin ilimin halittu na anti-VEGF, kuma idan RAS daji-nau'i, wani anti-EGFR far, Abinci da Drug Administration ya amince. trifluridine da tipiracil (LONSURF, Taiho Oncology, Inc.). LONSURF, maganin wakili guda ɗaya, ya riga ya sami izinin FDA don wannan amfani a cikin Satumba 2015.

A cikin SUNLIGHT (NCT04737187), bazuwar, lakabin buɗaɗɗe, multicenter, gwaji na duniya wanda ya kwatanta LONSURF tare da bevacizumab zuwa LONSURF guda ɗaya a cikin marasa lafiya 492 tare da ciwon daji na ciwon daji na metastatic wadanda suka sami matsakaicin tsarin maganin chemotherapy guda biyu kuma sun nuna ci gaban cutar su ko rashin haƙuri ga tsarin ƙarshe, aminci da inganci an kimanta.

Rayuwa gabaɗaya (OS) da tsira ba tare da ci gaba ba (PFS) sune mahimman ma'aunin sakamako na tasiri. Marasa lafiya da aka ba wa LONSURF ƙari bevacizumab hannun gwajin ya nuna haɓakar OS mai mahimmanci idan aka kwatanta da marasa lafiya da aka sanya wa hannun LONSURF (Hazard rabo 0.61; 95% CI: 0.49, 0.77; 1-gefe p0.001). Tsakanin OS na hannun LONSURF da bevacizumab shine watanni 10.8 (95% CI: 9.4, 11.8) kuma ga hannun LONSURF shine watanni 7.5 (95% CI: 6.3, 8.6). A cikin LONSURF da bevacizumab hannu, PFS na tsakiya shine watanni 5.6 (95% CI: 4.5, 5.9), yayin da a cikin hannun LONSURF, watanni 2.4 ne (95% CI: 2.1, 3.2) (Rashin haɗari: 0.44; 95% CI: 0.36, 0.54; 1-gefe p0.001).

Neutropenia, anemia, thrombocytopenia, gajiya, tashin zuciya, ƙara AST, ƙara ALT, ƙara yawan alkaline phosphatase, rage sodium, zawo, rashin jin daɗi na ciki, da rage cin abinci shine mafi yawan abubuwan da suka faru na gefe ko rashin daidaituwa na dakin gwaje-gwaje don LONSURF tare da bevacizumab (20%).

A ranakun 1 zuwa 5 da kwanaki 8 zuwa 12 na kowane zagayowar kwanaki 28, shawarar da aka ba da shawarar na LONSURF shine 35 mg/m2 ana sha da baki sau biyu a rana tare da abinci. Don cikakkun bayanai game da adadin bevacizumab, tuntuɓi bayanan da aka tsara.

Duba cikakken bayanin rubutawa don LONSURF.

Biyan kuɗi zuwa ga Newsletter

Sami sabuntawa kuma kada ku rasa bulogi daga Cancerfax

Toarin Don Bincika

Lutetium Lu 177 dotatate an amince da shi ta USFDA don marasa lafiya na yara masu shekaru 12 da haihuwa tare da GEP-NETS
Cancer

Lutetium Lu 177 dotatate an amince da shi ta USFDA don marasa lafiya na yara masu shekaru 12 da haihuwa tare da GEP-NETS

Lutetium Lu 177 dotatate, magani mai ban sha'awa, kwanan nan ya sami izini daga Hukumar Abinci da Magunguna ta Amurka (FDA) ga marasa lafiya na yara, wanda ke nuna gagarumin ci gaba a cikin ilimin cututtukan cututtukan yara. Wannan amincewar tana wakiltar alamar bege ga yara masu fama da ciwace-ciwacen ƙwayoyin cuta na neuroendocrine (NETs), nau'in ciwon daji da ba kasafai ba amma ƙalubale wanda galibi ke tabbatar da juriya ga hanyoyin warkewa na al'ada.

USFDA ta amince da Nogapendekin alfa inbakicept-pmln don cutar kansar mafitsara mara tsoka da BCG.
Ciwon daji na bladder

USFDA ta amince da Nogapendekin alfa inbakicept-pmln don cutar kansar mafitsara mara tsoka da BCG.

“Nogapendekin Alfa Inbakicept-PMLN, wani labari na rigakafi, yana nuna alƙawarin magance cutar kansar mafitsara idan aka haɗa shi da maganin BCG. Wannan sabuwar dabarar ta shafi takamaiman alamomin cutar kansa yayin da ake ba da amsa ga tsarin rigakafi, yana haɓaka ingancin jiyya na gargajiya kamar BCG. Gwajin gwaje-gwaje na asibiti suna bayyana sakamako masu ƙarfafawa, yana nuna ingantattun sakamakon haƙuri da yuwuwar ci gaba a cikin sarrafa kansar mafitsara. Haɗin kai tsakanin Nogapendekin Alfa Inbakicept-PMLN da BCG yana sanar da sabon zamani a cikin maganin cutar kansar mafitsara."

Ana buƙatar taimako? Ourungiyarmu a shirye take don taimaka muku.

Muna fatan samun lafiya cikin sauri na masoyinku da na kusa.

Fara hira
Muna Kan layi! Yi Taɗi da Mu!
Duba lambar
Hello,

Barka da zuwa CancerFax!

CancerFax wani dandali ne na majagaba wanda aka keɓe don haɗa mutane da ke fuskantar ciwon daji na zamani tare da hanyoyin kwantar da hankali kamar CAR T-Cell far, TIL far, da gwaji na asibiti a duk duniya.

Bari mu san abin da za mu iya yi muku.

1) Maganin ciwon daji a kasashen waje?
2) CAR T-Cell far
3) rigakafin cutar daji
4) Shawarar bidiyo ta kan layi
5) Maganin Proton